Biocircuits goes for speed over perfection

Opting for speed to market over perfection, Biocircuits Corp. has decided to reformulate the method used in its assay to measure thyroid dysfunction. Investors reacted with dismay, trimming 45 percent off BIOC shares, which closed Friday at $2.25.

The Sunnyvale, Calif., company 's ultimate goal is to produce point-of-care diagnostics